All Publications

Export 170 results:
Author Title Type [ Year(Asc)]
2010
Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study. Lodwick R, Sabin C, Porter K, Ledergerber B, van Sighem A, Cozzi-Lepri A, Khaykin P, Mocroft A, Jacobson L, De Wit S et al. Lancet, 2010 Jul 31, Volume 376, Issue 9738, p.340-5, (2010)
Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study. Gilson R, Man S, Copas A, Rider A, Forsyth S, Hill T, Bansi L, Porter K, Gazzard B, Orkin C et al. HIV Med, 2010 Feb, Volume 11, Issue 2, p.152-60, (2010)
The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. Ray M, Logan R, Sterne J, Hernández-Díaz S, Robins J, Sabin C, Bansi L, van Sighem A, de Wolf F, Costagliola D et al. AIDS, 2010 Jan 02, Volume 24, Issue 1, p.123-37, (2010)
The effect of transmitted HIV-1 drug resistance on pre-therapy viral load. Harrison L, Castro H, Cane P, Pillay D, Booth C, Phillips A, Geretti A and Dunn D. AIDS, 2010 Jul 31, Volume 24, Issue 12, p.1917-22, (2010)
Epidemiology of non-B clade forms of HIV-1 in men who have sex with men in the UK. Fox J, Castro H, Kaye S, McClure M, Weber J and Fidler S. AIDS, 2010 Sep 24, Volume 24, Issue 15, p.2397-401, (2010)
Factors influencing lopinavir and atazanavir plasma concentration. Stöhr W, Back D, Dunn D, Sabin C, Winston A, Gilson R, Pillay D, Hill T, Ainsworth J, Gazzard B et al. J Antimicrob Chemother, 2010 Jan, Volume 65, Issue 1, p.129-37, (2010)
HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United Kingdom. Chilton D, Castro H, Lattimore S, Harrison L, Fearnhill E, Delpech V, Rice B, Pillay D and Dunn D. Antivir Ther, 2010, Volume 15, Issue 7, p.985-91, (2010)
Impact of transmitted drug-resistance on treatment selection and outcome of first-line Highly Active Antiretroviral Therapy (HAART). Bansi L, Geretti A, Dunn D, Hill T, Green H, Fearnhill E, Gazzard B, Nelson M, Porter K, Phillips A et al. J Acquir Immune Defic Syndr, 2010 Apr, Volume 53, Issue 5, p.633-9, (2010)
Late diagnosis in the HAART era: proposed common definitions and associations with mortality. Sabin C, Schwenk A, Johnson M, Gazzard B, Fisher M, Walsh J, Orkin C, Hill T, Gilson R, Porter K et al. AIDS, 2010 Mar 13, Volume 24, Issue 5, p.723-7, (2010)
Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy. . Clin Infect Dis, 2010 May 01, Volume 50, Issue 9, p.1275-85, (2010)
Positive and negative drug selection pressures on the N348I connection domain mutation: new insights from in vivo data. Price H, Asboe D, Pozniak A, Gazzard B, Fearnhill E, Pillay D and Dunn D. Antivir Ther, 2010, Volume 15, Issue 2, p.203-11, (2010)
The prevalence of hepatitis C virus (HCV) infection in HIV-positive individuals in the UK - trends in HCV testing and the impact of HCV on HIV treatment outcomes. Turner J, Bansi L, Gilson R, Gazzard B, Walsh J, Pillay D, Orkin C, Phillips A, Easterbrook P, Johnson M et al. J Viral Hepat, 2010 Aug, Volume 17, Issue 8, p.569-77, (2010)
Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations. Bansi L, Sabin C, Delpech V, Hill T, Fisher M, Walsh J, Chadborn T, Easterbrook P, Gilson R, Johnson M et al. HIV Med, 2010 Aug, Volume 11, Issue 7, p.432-8, (2010)
Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. Lodwick R, Costagliola D, Reiss P, Torti C, Teira R, Dorrucci M, Ledergerber B, Mocroft A, Podzamczer D, Cozzi-Lepri A et al. Arch Intern Med, 2010 Mar 08, Volume 170, Issue 5, p.410-9, (2010)
2009
Is 1 alanine transaminase >200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort study. Bansi L, Turner J, Gilson R, Post F, Gazzard B, Leen C, Anderson J, Porter K, Hill T, Fisher M et al. J Acquir Immune Defic Syndr, 2009 Nov 01, Volume 52, Issue 3, p.391-6, (2009)
The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy. Sabin C, Smith C, Delpech V, Anderson J, Bansi L, Gilson R, Schwenk A, Leen C, Gazzard B, Porter K et al. HIV Med, 2009 Jan, Volume 10, Issue 1, p.35-43, (2009)
CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK. Bower M, Fisher M, Hill T, Reeves I, Walsh J, Orkin C, Phillips A, Bansi L, Gilson R, Easterbrook P et al. Haematologica, 2009 Jun, Volume 94, Issue 6, p.875-80, (2009)
Clinical epidemiology of HIV-associated end-stage renal failure in the UK. Bansi L, Hughes A, Bhagani S, Mackie N, Leen C, Levy J, Edwards S, Connolly J, Holt S, Hendry B et al. AIDS, 2009 Nov 27, Volume 23, Issue 18, p.2517-21, (2009)
Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Geretti A, Harrison L, Green H, Sabin C, Hill T, Fearnhill E, Pillay D and Dunn D. Clin Infect Dis, 2009 May 01, Volume 48, Issue 9, p.1296-305, (2009)
Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study. Bohlius J, Schmidlin K, Costagliola D, Fätkenheuer G, May M, Caro-Murillo A, Mocroft A, Bonnet F, Clifford G, Karafoulidou A et al. Antivir Ther, 2009, Volume 14, Issue 8, p.1065-74, (2009)
Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. Bohlius J, Schmidlin K, Costagliola D, Fätkenheuer G, May M, Murillo A, Mocroft A, Bonnet F, Clifford G, Touloumi G et al. AIDS, 2009 Sep 24, Volume 23, Issue 15, p.2029-37, (2009)
Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. Kesselring A, Wit F, Sabin C, Lundgren J, M Gill J, Gatell J, Rauch A, Montaner J, de Wolf F, Reiss P et al. AIDS, 2009 Aug 24, Volume 23, Issue 13, p.1689-99, (2009)
Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention? Grant A, Bansi L, Ainsworth J, Anderson J, Delpech V, Easterbrook P, Fisher M, Gazzard B, Gilson R, Gompels M et al. AIDS, 2009 Nov 27, Volume 23, Issue 18, p.2507-15, (2009)
Virological response to initial antiretroviral regimens containing abacavir or tenofovir. Bansi L, Sabin C, Gilson R, Gazzard B, Leen C, Anderson J, Dunn D, Hill T, Fisher M, Ainsworth J et al. J Infect Dis, 2009 Sep 01, Volume 200, Issue 5, p.710-4, (2009)
2008
Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression? Bansi L, Benzie A, Phillips A, Portsmouth S, Hill T, Leen C, Schwenk A, Johnson M, Anderson J, Gilson R et al. AIDS, 2008 Jan 30, Volume 22, Issue 3, p.349-56, (2008)